Immunization Station Age Immunization 2 months Vaxelis (DTaP-IPV/HepB/Hib) , Vaxneuvance (PCV15) , RotaTeq (RV5) 4 months Vaxelis (DTaP-IPV/HepB/Hib) , Vaxneuvance (PCV15) , RotaTeq (RV5) 6 months Vaxelis (DTaP-IPV/HepB/Hib) , Vaxneuvance (PCV15) , RotaTeq (RV5) , flu (eligible) 12 months M-M-R II , Varivax (Varicella) , Vaqta (Hep A) 15 months Vaxneuvance (PCV15) , Pentacel (DTaP-IPV/Hib) 18 months Vaqta (Hep A) 4 years ProQuad (MMR & Varicella) , Quadracel (DTaP-IPV) 11 years Adacel (Tdap) , Menquadfi (ACWY) , Gardasil (HPV)  16 years Menquadfi (ACWY) , Trumenba (Meningococcal B) Adacel (Tdap) Number of doses: 1 dose (booster) at 11–12 years old, then every 10 years. Spacing: Administer at least 5 years after the last tetanus-containing vaccine. Major teaching: Protects against tetanus, diphtheria, and pertussis. Critical for adolescents and adults to prevent pertussis transmission to infants. May cause mild pain or swelling at the injection site. Gardasil (HPV) Number of doses: 2 doses (6–12 months apart) for individuals starting at age 11–12 and under 15 years. 3 doses (0, 1–2, and 6 months) for individuals ≥15 years or immunocompromised. Spacing: Ensure a minimum interval of 5 months between the first and last doses. Major teaching: Protects against HPV-related cancers and genital warts. Most effective when given before exposure to HPV. May cause fainting; observe adolescents for 15 minutes post-vaccination. M-M-R II (Measles, Mumps, Rubella) Number of doses: 2 doses (at 12–15 months and 4–6 years). Spacing: Minimum interval: 4 weeks between doses. Major teaching: Live vaccine; avoid in immunocompromised individuals or during pregnancy. May cause mild fever or rash 1–2 weeks after vaccination. Critical for preventing measles outbreaks. Menquadfi (Meningococcal ACWY) Number of doses: 2 doses (at 11–12 years and 16 years). Spacing: At least 8 weeks between doses if additional doses are required for high-risk individuals. Major teaching: Protects against meningococcal disease (ACWY serogroups). Recommended for college students living in dormitories. May cause mild soreness at the injection site. Pentacel (DTaP-IPV/Hib) Number of doses: 4 doses (at 2, 4, 6, and 15–18 months). Spacing: Minimum interval of 4 weeks between doses in the primary series (2, 4, and 6 months). Booster dose at 15–18 months, spaced at least 6 months after the third dose. Major teaching: Combines protection against 5 diseases: diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b (Hib). Reduces the number of injections needed at each visit. Common side effects include mild fever, irritability, and injection site redness/swelling. Ensure parents are aware of the importance of completing the series for full protection against these diseases. ProQuad (MMR & Varicella) Number of doses: 2 doses (at 4–6 years and earlier if needed). Spacing: Minimum interval of 3 months between doses. Major teaching: Combines MMR and Varicella for convenience. Live vaccine; avoid in pregnancy or severe immunosuppression. Mild rash or fever may occur. Quadracel (DTaP-IPV) Number of doses: 1 dose at 4–6 years. Spacing: Must be spaced at least 6 months after the previous DTaP-IPV dose. Major teaching: Protects against diphtheria, tetanus, pertussis, and polio. Booster dose completes the series before entering school. RotaTeq (RV5) Number of doses: 3 doses (at 2, 4, and 6 months). Spacing: Minimum interval of 4 weeks between doses. Final dose must be administered before 8 months of age. Major teaching: Protects against severe rotavirus gastroenteritis. Oral vaccine; no injection required. Common side effects include mild diarrhea or fussiness. Trumenba (Meningococcal B) Number of doses: 2 doses (0 and 6 months apart). Spacing: A 3-dose schedule (0, 1–2, and 6 months) may be recommended for certain high-risk groups. Major teaching: Protects against meningococcal B disease, which can cause rapid and severe infections. Recommended for individuals 16–23 years old, especially those in high-risk settings (e.g., college campuses). Vaqta (Hep A) Number of doses: 2 doses (at 12 months and 18 months). Spacing: At least 6 months between doses. Major teaching: Protects against hepatitis A, a liver infection spread by contaminated food/water. Common side effects include mild injection site soreness. Varivax (Varicella) Number of doses: 2 doses (at 12–15 months and 4–6 years). Spacing: Minimum interval of 3 months between doses. Major teaching: Live vaccine; avoid in pregnancy or severe immunosuppression. Mild rash or fever may occur 1–2 weeks after vaccination. Vaxelis (DTaP-IPV/HepB/Hib) Number of doses: 3 doses (at 2, 4, and 6 months). Spacing: Minimum interval of 4 weeks between doses. Major teaching: Protects against six diseases (diphtheria, tetanus, pertussis, polio, hepatitis B, and Haemophilus influenzae type b). May cause mild fever, soreness, or swelling at the injection site. Vaxneuvance (PCV15) Number of doses: 4 doses (at 2, 4, 6, and 15 months). Spacing: Minimum interval of 4 weeks between primary doses. Booster dose recommended at least 8 weeks after the 3rd dose. Major teaching: Protects against 15 serotypes of Streptococcus pneumoniae , which can cause pneumonia, meningitis, and bacteremia. May cause mild fever or irritability post-vaccination. Flu Vaccine FluMist (Live Attenuated Influenza Vaccine - LAIV4) Type: Live attenuated vaccine administered intranasally. Age indications: Approved for healthy individuals aged 2–49 years. Effectiveness: Comparable to the flu shot in most years but may vary depending on the season and strains. Contraindications: Children <2 years or adults ≥50 years. Pregnant individuals. Immunocompromised individuals or close contacts of severely immunocompromised individuals (e.g., bone marrow transplant patients in protective isolation). Children 2–4 years with asthma or wheezing in the past 12 months. Severe allergy to any FluMist component. Major teaching: Avoid in individuals taking aspirin or salicylate-containing medications due to the risk of Reye's syndrome. Mild side effects include runny nose, sore throat, or headache. Flu Shot (Inactivated Influenza Vaccine - IIV4) Type: Inactivated vaccine administered via intramuscular injection. Age indications: Approved for individuals 6 months and older, including pregnant individuals and those with chronic health conditions. Effectiveness: Provides broad protection against circulating influenza strains; updated yearly to match predicted strains. Contraindications: Severe allergy to any flu shot component, including egg protein (though egg-free formulations are available). Major teaching: Common side effects include mild soreness or swelling at the injection site, low-grade fever, or fatigue. Safe for individuals with chronic medical conditions or weakened immune systems. For children <9 years receiving the flu vaccine for the first time, 2 doses are required at least 4 weeks apart. Key Differences: Aspect FluMist (Nasal Spray) Flu Shot (Injection) Type of Vaccine Live attenuated Inactivated Route of Administration Nasal spray Intramuscular injection Age Range 2–49 years 6 months and older Pregnancy Safe? No Yes Immunocompromised Use? No Yes Common Side Effects Runny nose, sore throat, headache Soreness, redness, low-grade fever